Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: Incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara centre

Pediatric Endocrinology Reviews

Volumn 6, Issue SUPPL. 1, 2008, Pages 158-169

  Gamberini, Maria Rita ^a   de Sanctis, Vincenzo ^a   Gilli, Giuseppe ^a  

^a S ANNA HOSPITAL   (Italy)

Author keywords

Chelation therapy; Endocrine complications; Iron overload; Thalassaemia major

Indexed keywords

ASCORBIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INCIDENCE; IRON CHELATION; IRON OVERLOAD; ITALY; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENARCHE; MONOTHERAPY; PATIENT COMPLIANCE; PREVALENCE; PUBERTY; RISK FACTOR; SECONDARY AMENORRHEA; SPLENECTOMY; THALASSEMIA MAJOR; TREND STUDY;

ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; COHORT STUDIES; DIABETES MELLITUS; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INCIDENCE; IRON CHELATING AGENTS; IRON OVERLOAD; ITALY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 58149522761     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Bergeron C, Kovacs K. Pituitary siderosis. A histologic, immunocytoytologic and ultrastructural study. Am J Pathol 1978;93:295-309
2. Costin G, Kogut MD, Hyman CB, Ortega A. Endocrine abnormalities in thalassemia major. Am J Dis Child 1979;133:497-502
3. De Luca F, Melluso R, Sobbrio G, Canfora G, Trimarchi F. Thyroid function in thalassaemia major. Arch Dis Child 1980;55:389-392
4. Sabato AR, De Sanctis V, Atti G, Capra L, Bagni B, Vullo C. Primary hypothyroidism and low T3 syndrome in thalassemia major. Arch Dis Child 1983;58:120-127
5. Magro S, Puzzonia P, Consarino C, Galati MC, Morgione S, Porcelli D, Grimaldi S, Tancrè D, Arcuri V, De Sanctis V, Alberti A. Hypothyroidism in patients with thalassemia syndromes. Acta Haematol 1990;84:72-76
6. Vullo C, De Sanctis V, Katz M, Wonke B, Hoffbrand AV, Bagni B, Torresani T, Tolis G, Masiero M, Di Palma A, Borgatti L. Endocrine abnormalities in thalassemia. Ann NY Acad Sci 1990;612:293-310
7. Agarwal MB, Vishwanathan C, Rajadhyksha G, Bhave AA, Billa V, Malkan G, Bajoa K. Thyroid dysfunction in multi-transfused iron overload thalassemia patients. Indian Pediatrics 1992;29:997-1002
8. Italian Working Group on Endocrine Complications in Non-Endocrine Disease. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol 1995;42:581-586
9. Cao A, Galanello R, Rosatelli MC, Argiolu F, De Virgilis S. Clinical experience of management of thalassemia: the Sardinian experience. Sem Hematol 1996;33:66-75
10. Senanayake MP, Suraweera S, Hubert HDM. Thyroid function in thalassaemia major. Ceylon Med J 1999;44:166-168
11. Zervas A, Katopodi A, Protonotariou A, Livadas S, Karagiorgia M, Politis C, Tolis G. Assessment of thyroid function in two hundred patients with beta-thalassemia major. Thyroid 2002;12:151-154
12. De Sanctis V, Eteftheriou A, Malaventura C, on behalf of the Thalassaemia International Federation Study Group on Growth and Endocrine Complication in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassemia major: a multicenter study by the Thalassaemia International Federation. Pediatr Endocrinol Rev 2004;2(Suppl 2):249-255
13. Cunningham MJ, Macklib WA, Neufeld EJ, Choen AR. Complications of beta-thalassemia major in North America. Blood 2004;104:34-39
14. Jaruratanasirikul S, Laosombat V, Sangsupavanich P, Leetanaporn K. Thyroid function in beta-thalassemic children receiving hypertransfusions with suboptimal iron-chelating therapy. J Med Assoc Thai 2007;90:1798-1802
15. Kidson-Gerber G, Francis S, Lindeman R. Management and clinical outcomes of transfusion-dependent thalassaemia in an Australian tertiary referral clinic. MJA 2008;188:72-75
16. Alagna S, Masala A, Gallisai D, Giannini A, Burrai C, Pinna A, Rassu S, Ravasii P, Devilla L. Parathyroid function and bone metabolism in children with beta thalassaemia major: effects of sex steroid treatment. Eur J Med 1992;1:153-157
17. De Sanctis V, Vullo C, Bagni B, Chiccoli L. Hypoparathyroidism in beta-thalassemia major. Acta Haematol 1992;88:105-108
18. Aleem A, Al-Momen AK, Al-Harakati MS, Hassan A, Al-Fawwaz I. Hypocalcemia due to hypoparathyroidism in beta-thalassemia major patients. Ann Saudi Med 2000;20:344-346
19. Chern JPS, Kai-Hsin L. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Pediatr Hematol Oncol 2002;24:291-293
20. Economou M, Katzos G, Koussi A, Tsara A, Athanassiou-Metaxa M. Hypoparathyroidism in beta-thalassemic patients. J Pediatr Hematol Oncol 2003;25:275
21. Angelopoulos NG, Goula A, Rombopoulos G, Kaltzidou V, Katounda E, Kaltsas D, Tolis G. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Bone Miner Metab 2006;24:138-145
22. Flynn DM, Farney A, Jackon D, Clayton BE. Hormonal changes in thalassaemia major. Arch Dis Child 1976;51:826-836
23. Zuppinger K, Molinari B, Hirt A, Imbach P, Gugler E, Tonz O, Zurbrugg RP. Increased risk of diabetes mellitus in beta-thalassemia major. Helv Ped Acta 1978;34:197-207
24. Capra L, Atti G, De Sanctis V, Candini C. Glucose tolerance and chelation therapy in patients with thalassaemia major. Haematologica 1983;68:63-68
25. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassemia. Arch Dis Child 1988;63:58-62
26. El-Hazami MA, Al-Swailem A, Al-Fawaz I, Waesey SA, Al-Swailem A. Diabetes mellitus in children suffering from thalassemia major. J Trop Pediatr 1994;40:261-266
27. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complication in patients with thalassaemia major. Pediatr Endocrinol Rev 2007;5:642-648
28. Cario H, Stanke K, Kohne E. Epidemiologic situation and treatment of patients with thalassemia major in Germany: results of German multicenter beta-thalassemia study. Ann Hematol 2000;79:7-12
29. Shalitin S, Carmi D, Weintrob N, Philip M, Kornreich L, Zilber R, Yaniv I, Tamary H. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005;74:93-100
30. Oayeri H, Oloomi Z. Prevalence of growth and pubertal failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. Arch Iran Med 2006;9:329-334
31. Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanctis V, Melevendi C, Naselli A, Masera G, Terzoli S, Gabutti V, Piga A. Growth and sexual maturation in thalassemia major. J Pediatr 1985;106:150-155
32. De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. Italian Working Group on Endocrine Complications in Non-Endocrine Disease. Impact of long-term iron chelation therapy on growth and endocrine function in thalassaemia. J Pediatr Endocrinol Metab 2006;19:417-480
33. Padimas J, Goulis DG, Mandala E, Georgiadis G, Zournati V, Tarlatzis BC, Bontis JN. Beta-thalassemia and gonadal axis: a cross sectional study in a Greek population. Hormones 2002;1:179-187
34. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193
35. Gamberini MR, Fortini M, De Sanctis V, Gilli G, Tetsa R. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Ped Endocrinol Rev 2004;2(Suppl 2):285-291
36. World Health Organization. WHO Expert Committee on Diabetes Mellitus, 2nd Report. Geneva: Who Technical Report Series 1980;646:1-80
37. Tanner JM. Growth at adolescence. Second edition. Oxford: Blackwell Science 1973 pp 32
38. Zachmann M, Prader A, Kird HP, Hafliger H. Testicular volume during adolescence: cross sectional and longitudinal studies. Helv Paediatr Acta 1974;29:61-72
39. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-578
40. Sonakul D. Endocrine pathology in thalassemia. In: Ando' S, Brancati C, eds. Endocrine disorders in thalassemia. Berlin-Heidelberg: Springer-Verlag 1995
41. Tatò L, Lahiou N, Zamboni G, De Sanctis V, De Luca F, Arrigo T, Antoniazzi F, Roger M. Impaired responses of free alpha-subunits after luteinizing hormone-releasing hormone stimulation in beta-thalassemia major. Horm Res 1993;39:213-217
42. Jensen CE, Tuck CM, Morris RW, Yardumian A, De Sanctis V, Hoffbrand AV, Wonke B. Incidence of endocrine complications and clinical disease severity related to genotype analysis in patients with beta-thalassemia. Eur J Haematol 1997;59:76-81
43. Skordis N, Michealidu M, Savva SC, Ioannou Y, Rousounides A, Kleathous M, Skordos G, Christou S. The impact of genotype on endocrine complications in thalassaemia major. Eur J Haematol 2006;77:150-156
44. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36
45. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos, Tolls G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Brit J Hematol 2006;134:438-444
46. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechuad R, Belleti R, Alberti D. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica 2006;91:1343-1351